Bristol Myers Squibb has announced positive topline results from its phase 3 trial of Reblozyl (luspatercept-aamt), the first erythroid maturation agent for first-line treatment of patients with ...
Jan Frayne’s group in the School of Biochemistry renowned for the creation of the Bristol Erythroid Line – Adult (BEL-A ... to study erythropoiesis in disease states and for use in the development of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback